Safety of the Bispecific Antibody, REGN5458, in Multiple Myeloma Patients
Dr. Jeffrey Zonder, MD, of the Barbara Ann Karmanos Cancer Institute, discusses data from the first-in-human study testing REGN5458 for relapsed/refractory multiple myeloma.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
